

SESSION LISTINGS:

FRS Featured Research Session
LPR Lightning Presentation Round
PER Perspectives Session

PL Plenary Session
DEV Developing Topics (not currently listed)

Other activities will take place in Exhibit Hall, including ASK! sessions and poster sessions.

Sunday, July 16

8 - 8:45 a.m.		LPR: Clinical Manifestations					
8:45 - 9:15 a.m.							
9:15 - 10:30 a.m.		FRS: Towards clinical implementation of Centiloid quantification: Lessons learned from the AMYPAD consortium	FRS: The complex relationship between APOE and glial cells	PER: New horizons on human postmortem neuropathology	FRS: Alzheimer's disease biomarkers in diverse populations	FRS: The role of early life adversity in cognitive decline and dementia	FRS: Meaningfulness of Clinical Trial Outcomes in Alzheimer's Disease: Translation of Results to Patients
10:30 - 11:15 a.m.							
11:15 a.m. - 12:30 p.m.	PL: Rik Ossenkoppele - Tau PET: towards implementation in trials and clinical practice						
12:30 - 2:15 p.m.							
2:15 - 3:30 p.m.		FRS: Clinical applications of tau PET	FRS: T cells in brain aging and neurodegeneration	FRS: Beyond the classics: Revamping our knowledge on human neuropathology in neurodegenerative diseases	FRS: Diversity-informed approaches to dementia care	FRS: Psychosocial and other experiential factors at micro- and meso-levels related to dementia risk from middle into older age	FRS: Maximizing learning and efficiency of clinical trials with data sharing and effective biorepositories
3:30 - 4:15 p.m.							
4:15 - 5:30 p.m.	FRS: Diagnosis, Staging, and Characterization of Alzheimer's Disease: Report from the Alzheimer's Association Workgroup	FRS: Novel insights into tau biology in AD and other tauopathies	FRS: ApoE impact and novel therapeutic modalities in Alzheimer's brain	FRS: Redefining frontiers of neuropathologic changes in aging and neurodegenerative diseases	FRS: Global and equitable study designs in aging research and subsequent research yields and the expansion of the field	FRS: Improving dementia care through technology and digital interventions	FRS: Looking Under the Hood of AD Prevention Trials: Analytic Approaches for Cognitive and Biomarker Outcomes

Monday, July 17

8 - 8:45 a.m.		LPR: Basic Science	LPR: Drug Development				
8:45 - 9:15 a.m.							
9:15 - 10:30 a.m.		FRS: Building therapeutic pipeline: Tau related targets and therapy development	FRS: Neuroimmune Function in Neurodegenerative Disease	PER: TDP-43 proteinopathy in neurodegenerative diseases: current understanding of pathobiology and development of therapeutics and diagnostics	FRS: Patient and public involvement in dementia research: Global perspectives	FRS: Hearing loss and dementia: cause, consequence or catalyst?	FRS: Modeling longitudinal cognitive decline in aging and Alzheimer's disease
10:30 - 11:15 a.m.							
11:15 a.m. - 12:30 p.m.	PL: Cristian Lasagna-Reeves - Bassoon contributes to tau-seed propagation and neurotoxicity PL: Cynthia Lemere - The Evolving Role of Complement in Alzheimer's Disease						
12:30 - 2:15 p.m.							
2:15 - 3:30 p.m.		FRS: Modeling longitudinal disease processes using amyloid and tau PET	PER: Neurodegeneration and inflammation	FRS: Fluid biomarkers of fronto-temporal dementia, Lewy body disease and TDP-43 proteinopathies	FRS: Successful Recruitment of Underrepresented Groups in AD Studies	FRS: Sensory loss and sleep disturbances in persons with dementia and their care partners	FRS: Psychiatric and neuropsychiatric syndromes
3:30 - 4:15 p.m.							
4:15 - 5:30 p.m.		FRS: Novel fluid biomarkers of Alzheimer's disease	FRS: Tracking glial contributions to Alzheimer's disease etiology and progression	FRS: Latest advances and future perspectives in biomarkers for Dementia with Lewy bodies	PER: Addressing the disparities in dementia risk, early detection and care in US Latino populations: Insights from the US Consortium of Aging, Dementia and Latino Studies (CADLAS)	FRS: Sleep and brain health: associations and mechanisms	PER: The interface of cognition and behavior for dementia risk

Tuesday, July 18

8 - 8:45 a.m.		LPR: Dementia Care	LPR: Biomarkers				
8:45 - 9:15 a.m.							

9:15 - 10:30 a.m.		PER: Advances in plasma Alzheimer's disease biomarkers	FRS: New horizon therapeutics targeting the immune system in Alzheimer's disease	ECBS: What can we learn from multi-omics?	PER: Dementia care in low- and middle-income countries	FRS: Non-pharmacologic risk reduction strategies for Alzheimer's disease prevention: one size does not fit all?	FRS: Proving the Evidence Base for Nationwide Caregiver Programs: Successes and Challenges
10:30 - 11:15 a.m.							
11:15 a.m. - 12:30 p.m.	PL: Marsel Mesulam - The aphasic dementia of Alzheimer's Disease Adesola Ogunniyi - The epidemiology of dementia in Africa						
12:30 - 2:15 p.m.							
2:15 - 3:30 p.m.	ECBS: Endolysosomal pathways and their importance in neurodegenerative diseases	FRS: Blood-based biomarkers in Alzheimer's disease	FRS: The vascular contribution to Alzheimer's disease pathology and brain structure	FRS: The Alzheimer's Disease Sequencing Project: Recent Advances and Update of Results.	PER: Opportunities and challenges to promote equity in the dementia diagnosis and care in the current landscape of advanced (but less accessible) diagnostic tools and treatment options: The GBHI experience	FRS: New developments in dementia risk prediction scores, profiles and methods	FRS: Cognitive and non-cognitive aspects of dementia
3:30 - 4:15 p.m.							
4:15 - 5:30 p.m.		FRS: Novel methods of detection of α-synuclein pathology and their relevance for Alzheimer's and Lewy body disease research, practice and trials	ECBS: Is it all in the vessels? Understanding the role of the vascular system in dementia	BS, FRS: Genotype-phenotype insights from atypical Alzheimer's disease	PH, PER: Alzheimer's disease and related dementias (AD/ADRD) research in Low- and Middle-Income Countries (LMICs)	PH, FRS: Non-pharmacological interventions and lifestyle changes to prevent cognitive decline and dementia	FRS: Dyadic patterns of subjective cognitive change: Addressing key knowledge gaps to facilitate ADRD research along the early disease continuum

Wednesday, July 19

8 - 8:45 a.m.		LPR: Public Health					
8:45 - 9:15 a.m.							
9:15 - 10:30 a.m.		FRS: Incidence, pathogenesis, and clinical implications of amyloid related imaging abnormalities (ARIA)	FRS: Cerebrovascular features associated with increased APP dosage in Down syndrome and duplication of the APP locus (DupAPP)	FRS: Multiomics approaches to understanding AD/RD development	FRS: Sex and gender specific risk factors for cognitive decline and neurodegeneration	PER: Novel approaches to address caregiver burden and stress	
10:30 - 11:15 a.m.							

11:15 a.m. - 12:30 p.m.	PL: Rachelle Doody, John Sims, Michael Irizarry - Amyloid reduction and evidence of downstream biomarker modification						
12:30 - 2:15 p.m.							
2:15 - 3:30 p.m.	FRS: World Alzheimer Report 2022: Dementia treatment, care and support – are global health systems ready for what's next?	FRS: The role of neuroimaging in the era of anti-amyloid therapies: challenges and opportunities in research and clinical praxis.	PER: Emerging biomarkers for common co-pathologies	FRS: Modern concepts and approaches in polygenic score analysis of Alzheimer's disease	PER: Closing the sex/gender gap in dementia: homing in on the vasculature	FRS: Exploring dementia care best practices and approaches to improve outcomes in a variety of settings and populations	PER: Retinal imaging and its potential role in future clinical practice for Alzheimer's disease
3:30 - 4:15 p.m.							
4:15 - 5:30 p.m.	FRS: Implementation of plasma AD biomarkers in diverse community-based and primary care settings	FRS: Imaging brain connectivity and function	FRS: The selective vulnerability of the neuromodulatory subcortical systems: mechanisms underlying Alzheimer's disease risk	FRS: Novel GWAS approaches in ADRD	FRS: Clinical and neuroimaging correlates of neuropathologic changes: roles of age, sex and comorbidities		PER: International Centers for Alzheimer Research: key players for research, education and societal outreach of Alzheimer's disease

Thursday, July 20							
8 - 9:15 a.m.		FRS: New clinical candidates and learnings from anti-amyloid therapeutic trials	FRS: The complex relationship between TBI and ADRD	FRS: Proteins for profiling and understanding Alzheimer's disease	FRS: Metabolic and hormonal connections to AD	FRS: Modifiable risk factors and multimorbidities in dementia	FRS: Advancement of human cell-based Alzheimer's disease modeling
9:15 - 9:45 a.m.							
9:45 - 11:00 a.m.	PL: Ana Quiñones - An agenda for addressing multimorbidity and racial and ethnic disparities						
11:00 - 11:30 a.m.							
11:30 a.m. - 12:45 p.m.	FRS: The prognostic utility of blood-based biomarkers		FRS: Imaging in fronto-temporal dementia, LATE and chronic traumatic encephalopathy	FRS: Integrating genetics, biomarkers and endophenotypes in mice and humans	FRS: Metabolic and systemic diseases: Associations with dementia and cognition	FRS: Preclinical therapeutic targets and early phase studies	PER: Highlights of the Alzheimer's Association International Conference (in Dutch)